Rare Diseases
Commons · Question 81025 · Tabled 10 Oct 2025 · Department of Health and Social Care · Official record
Answered 6 Nov 2025
Question
Asked by Joshua Reynolds
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the National Institute for Health and Care Excellence not having updated its methods on evaluating the wider societal costs of rar
Answer
Answered by Zubir Ahmed, 6 Nov 2025
There are no plans to introduce a separate evaluation process for orphan medicines. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether all new licensed medicines, including medicin...